Tissue factor - A therapeutic target for thrombotic disorders

Expert Opinion on Therapeutic Targets

Volumn 6, Issue 2, 2002, Pages 159-174

  Houston, Donald S ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Atherosclerosis; Cancer; Coagulation; Monocytes; Sepsis; Thrombosis; Tissue factor

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTICOAGULANT PROTEIN; ANTISENSE OLIGONUCLEOTIDE; BLOOD CLOTTING FACTOR 10; BLOOD CLOTTING FACTOR 7A; C PEPTIDE; COLECALCIFEROL; COLECALCIFEROL DERIVATIVE; CORTICOSTEROID; CYTOKINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 4; LOW MOLECULAR WEIGHT HEPARIN; MEMBRANE PROTEIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; PROSTAGLANDIN E2 DERIVATIVE; PROSTANOID; PROTEINASE INHIBITOR; RETINOIC ACID; THROMBOCYTE ANTIBODY; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNINDEXED DRUG; WARFARIN;

ANTICOAGULANT THERAPY; ATHEROSCLEROTIC PLAQUE; BLEEDING; BLOOD CLOTTING; BLOOD VESSEL INJURY; CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG BINDING; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG FORMULATION; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG TARGETING; ENDOTHELIUM CELL; HUMAN; MONOCYTE; NEMATODE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; RISK ASSESSMENT; SEPSIS; SIGNAL TRANSDUCTION; THROMBOSIS;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIBODIES, MONOCLONAL; ARTERIOSCLEROSIS; BLOOD COAGULATION; CLINICAL TRIALS; CYTOKINES; DRUG DESIGN; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; FACTOR VIIA; FIBRINOLYTIC AGENTS; GLYCOPROTEINS; HELMINTH PROTEINS; HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPOPROTEINS; MICE; MONOCYTES; MULTIPROTEIN COMPLEXES; NEOPLASMS; OLIGONUCLEOTIDES, ANTISENSE; PROSTAGLANDINS; SIGNAL TRANSDUCTION; SWINE; SWINE, MINIATURE; THROMBOPHILIA; THROMBOPLASTIN; THROMBOSIS;

EID: 0036243671     PISSN: 14728222     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728222.6.2.159     Document Type: Review

References (154)

1. Coagulation cascade: An overview
2. Selective cellular expression of tissue factor in human tissues. Implications for disorders of hemostasis and thrombosis
3. Tissue factor and factor VII initiation of coagulation
4. Functional tissue factor is entirely cell surface expressed on lipopolysaccharide-stimulated human blood monocytes and a constitutively tissue factor-producing neoplastic cell line./
5. Regulation of tissue factor initiated thrombin generation by the stoichiometric inhibitors tissue factor pathway inhibitor, antithrombin-III and heparin cofactor-II
6. Cytokines and hemostasis
7. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity
8. Interferon-gamma and lipopolysaccharide potentiate monocyte tissue factor induction by C-reactive protein: Relationship with age, sex and hormone replacement treatment
9. Platelet-derived growth factor-BB and monocyte chemotactic protein-1 induce human peripheral blood monocytes to express tissue factor
10. Induction of monocyte tissue factor expression by homocysteine: A possible mechanism for thrombosis
11. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE
12. Thromboplastin (Factor III) activity in human monocytes induced by immune complexes
13. C-reactive protein induces human peripheral blood monocytes to synthesize tissue factor
14. Effects of alpha 1-acid glycoprotein on tissue factor expression and tumor necrosis factor secretion in human monocytes
15. Monocytes and tissue factor promote thrombosis in a murine model of oxygen deprivation
16. Modulation of the endothelial procoagulant response to lipopolysaccharide and tumour necrosis factor-alpha in-vitro: The effects of dexamethasone, pentoxifylline, iloprost and a polyclonal antihuman IL-1 alpha antibody
17. Lipopolysaccharide induction of tissue factor expression in rabbits
18. Expression of tissue factor, thrombomodulin and E-selectin in baboons with lethal Escherichia coli sepsis
19. Enhanced endothelial tissue factor but normal thrombomodulin in endotoxin-treated rabbits
20. The expression of surface tissue factor apoprotein by blood monocytes in the course of infections in early infancy
21. Increased tissue thromboplastin activity in monocytes of patients with meningococcal infection: Related to an unfavourable prognosis
22. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease
23. Monocyte expression of tissue factor and adhesion molecules: The link with accelerated coronary artery disease in patients with chronic renal failure
24. Enhanced expression of monocyte tissue factor in patients with liver cirrhosis
25. Blood coagulation in patients with benign and malignant tumours before and after surgery. Special reference to thromboplastin generation in monocytes
26. Thromboplastin activity of blood monocytes after total hip replacement
27. Lipoprotein associated coagulation inhibitor, factor VII, antithrombin III and monocyte tissue factor following surgery
28. Generation of tissue factor by patient monocytes: Correlations to thromboembolic complications
29. Regulation of monocyte procoagulant activity in acute myocardial infarction: Role of tissue factor and tissue factor pathway inhibitor-1
30. Monocyte tissue factor-like activity in post myocardial infarction patients
31. The in vivo kinetics of tissue factor messenger RNA expression during human endotoxemia: Relationship with activation of coagulation
32. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein
33. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia
34. Evidence for time-dependent activation of monocytes in the systemic circulation in unstable angina but not in acute myocardial infarction or stable angina
35. Increased monocyte tissue factor expression in coronary disease
36. Measurement of tissue factor activity in whole blood
37. Activation of monocytes, T-lymphocytes and plasma inflammatory markers in angina patients
38. Monocytes express tissue factor in young patients with cerebral ischemia
39. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients
40. Simultaneous elevation of the levels of circulating monocyte chemoattractant protein-1 and tissue factor in acute coronary syndromes
41. Significant correlations between tissue factor and thrombin markers in trauma and septic patients with disseminated intravascular coagulation
42. Polymorphisms in the 5′ regulatory region of the tissue factor gene and the risk of myocardial infarction and venous thromboembolism: The ECTIM and PATHROS studies
43. Plaque rupture, thrombosis and therapeutic implications
44. Regulation of the procoagulant response to arterial injury
45. Tissue factor expression on macrophages in coronary plaques in patients with unstable angina
46. Tissue factor: An enzyme cofactor and a true receptor
47. Regulation of vascular endothelial growth factor production and angiogenesis by the cytoplasmic tail of tissue factor
48. Tissue factor as a tumor procoagulant
49. Expression of tissue factor by melanoma cells promotes efficient hematogenous metastasis
50. Requirement for binding of catalytically active Factor VIIa in tissue factor-dependent experimental metastasis
51. Role of tissue factor in metastasis: Functions of the cytoplasmic and extracellular domains of the molecule
52. Tissue factor expression in human colorectal carcinoma: Correlation with hepatic metastasis and impact on prognosis
53. Tissue factor expression and metastatic potential of colorectal cancer
54. The prevalence and associated variables of deep venous thrombosis in patients with advanced cancer
55. Pathogenesis of thrombosis in patients with malignancy
56. Procoagulant activity in whole blood from patients with breast and colorectal cancer
57. Urinary tissue factor levels in patients with breast and colorectal cancer
58. Abnormalities of blood coagulation in patients with cancer
59. Monocyte tissue factor levels in patients with urological tumours: An association between tumour presence and progression
60. Increased production of mononuclear cell procoagulant activity in Hodgkin's disease
61. Monocyte tissue factor in treated Hodgkin's disease
62. Clinical risk factors and timing of recurrent venous thromboembolism during the initial 3 months of anticoagulant therapy
63. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy
64. Low-molecular-weight heparin therapy and mortality
65. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide
66. IL-10 inhibits LPS-induced human monocyte tissue factor expression in whole blood
67. IL-4 and IL-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes
68. Inhibition of IL-1 induced tissue factor (TF) synthesis and procoagulant activity (PCA) in purified human monocytes by IL-4, IL-10 and IL-13
69. Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines
70. The stable prostacyclin analog, iloprost and prostaglandin E1 inhibit monocyte procoagulant activity in vitro
71. Effect of cyclic AMP and cyclic GMP on thromboplastin (factor III) synthesis in human monocytes in vitro
72. Pentoxifylline inhibition of procoagulant activity generated by activated mononuclear phagocytes
73. Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees
74. Pentoxifylline prevents upregulation of monocyte tissue factor in renal transplant recipients undergoing post-graft complications
75. Anticoagulant effects of 1alpha, 25-dihydroxyvitamin D3 on human myelogenous leukemia cells and monocytes
76. 1α,25-dihydroxyvitamin D(3) and its potent synthetic analogs downregulate tissue factor and upregulate thrombomodulin expression in monocytic cells, counteracting the effects of tumor necrosis factor and oxidized LDL
77. Beneficial effect of the active form of vitamin D3 against LPS-induced DIC but not against tissue-factor-induced DIC in rat models
78. Retinoic acid reduces induction of monocyte tissue factor and tissue factor/factor VIIa-dependent arterial thrombus formation
79. Retinoic acid selectively inhibits lipopolysaccharide induction of tissue factor gene expression in human monocytes
80. Dexamethasone enhances agonist induction of tissue factor in monocytes but not in endothelial cells
81. Angiotensin-converting enzyme inhibitors downregulate tissue factor synthesis in monocytes
82. Effects of blockade of the renin-angiotensin system on tissue factor and plasminogen activator inhibitor-1 synthesis in human cultured monocytes
83. Angiotensin-converting enzyme inhibition reduces monocyte chemoattractant protein-1 and tissue factor levels in patients with myocardial infarction
84. Vastatins inhibit tissue factor in cultured human macrophages. A novel mechanism of protection against atherothrombosis
85. Inhibition of tissue-factor-mediated thrombin generation by simvastatin
86. Simvastatin attenuates vascular hypercoagulability in cardiac transplant recipients
87. Suppression of human monocyte tissue factor synthesis by antisense oligodeoxynucleotide
88. Role of NF-κB in the mortality of sepsis
89. Intravenous somatic gene transfer with antisense tissue factor restores blood flow by reducing tumor necrosis factor-induced tissue factor expression and fibrin deposition in mouse meth-A sarcoma
90. The role of platelets in decrypting monocyte tissue factor
91. Granulocytes enhance LPS-induced tissue factor activity in monocytes via an interaction with platelets
92. Platelet activating factor enhancement of lipopolysaccharide-induced tissue factor activity in monocytes: Requirement of platelets and granulocytes
93. Blood-borne tissue factor: Another view of thrombosis
94. Generation of a humanized, high affinity anti-tissue factor antibody for use as a novel antithrombotic therapeutic
95. A monoclonal antibody against rabbit tissue factor inhibits thrombus formation in stenotic injured rabbit carotid arteries
96. Antithrombotic effect of a monoclonal antibody against tissue factor in a rabbit model of platelet-mediated arterial thrombosis
97. Coli septic shock is prevented by blocking tissue factor with monoclonal antibody
98. Complete inhibition of endotoxin-induced coagulation activation in chimpanzees with a monoclonal Fab fragment against factor VII/VIIa
99. Active site modification of factor VIIa affects interactions of the protease domain with tissue factor
100. Active site-blocked activated factor VII as an effective antithrombotic agent: Mechanism of action
101. Antithrombotic effects of recombinant human, active site-blocked Factor VIIa in a rabbit model of recurrent arterial thrombosis
102. Recombinant human, active site-blocked Factor VIIa reduces infant size and noreflow phenomenon in rabbits
103. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model
104. Sequential injury of the rabbit abdominal aorta induces intramural coagulation and luminal narrowing independent of intimal mass. Extrinsic pathway inhibition eliminates luminal narrowing
105. Antithrombotic and antilesion benefits without hemorrhagic risks by inhibiting tissue factor pathway
106. Future possibilities in the regulation of the extrinsic pathway: rFVIIa and TFPI
107. Prevention of experimental arterial thrombosis by topical administration of active site-inactivated factor VIIa
108. Local application of recombinant active-site inhibited human clotting Factor VIIa reduces thrombus weight and improves patency in a rabbit venous thrombosis model
109. Endarterectomy for asymptomatic carotid artery stenosis. Executive committee for the asymptomatic carotid atherosclerosis study
110. Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. North American symptomatic carotid endarterectomy trial collaborators
111. Active site inhibited factor VIIa (DEGR VIIa) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to LD100 Escherichia coli
112. Coagulation blockade prevents sepsis-induced respiratory and renal failure in baboons
113. Structure and biology of tissue factor pathway inhibitor
114. Tissue factor pathway inhibitor gene disruption
115. Low levels of heparinreleasable tissue factor pathway inhibitor in young patients with thrombosis
116. Deficiency of tissue factor pathway inhibitor promotes atherosclerosis and thrombosis in mice
117. Efficacy of unfractionated heparin, low molecular weight heparin and both combined for releasing total and free tissue factor pathway inhibitor
118. Heparin requires both antithrombin and extrinsic pathway inhibitor for its anticoagulant effect in human blood
119. Depletion of intravascular pools of tissue factor pathway inhibitor (TFPI) during repeated or continuous intravenous infusion of heparin in man
120. Reactivation of unstable angina after the discontinuation of heparin
121. Differential effect of unfractionated heparin and low molecular weight heparin on intravascular tissue factor pathway inhibitor: Evidence for a difference in antithrombotic action
122. Fucoidan, as heparin, induces tissue factor pathway inhibitor release from cultured human endothelial cells
123. Endogenous release of tissue factor pathway inhibitor by topical application of an ointment containing mucopolysaccharide polysulfate to nonhuman primates
124. Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters
125. Recombinant full-length tissue factor pathway inhibitor (TFPI) prevents thrombus formation and rethrombosis after lysis in a rabbit model of jugular vein thrombosis
126. Antithrombotic effect of recombinant truncated tissue factor pathway inhibitor (TFPI1-161) in experimental venous thrombosis-a comparison with low molecular weight heparin
127. Inhibition of tissue factor reduces thrombus formation and intimal hyperplasia after porcine coronary angioplasty
128. Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after balloon-induced arterial injury in minipigs
129. Tissue factor pathway inhibitor attenuates procoagulant activity and upregulation of tissue factor at the site of balloon-induced arterial injury in pigs. Arterioscler
130. Prevention of thrombosis by topical application of tissue factor pathway inhibitor in a rabbit model of vascular trauma
131. Prevention of microvascular thrombosis by topical application of recombinant tissue factor pathway inhibitor
132. A Phase II trial of intraluminal irrigation with recombinant human tissue factor pathway inhibitor to prevent thrombosis in free flap surgery
133. Pretreatment of a Dacron graft with tissue factor pathway inhibitor decreases thrombogenicity and neointimal thickness: A preliminary animal study
134. Topically applied tissue factor pathway inhibitor reduced intimal thickness of small arterial autografts in rabbits
135. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock
136. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon Gram-negative model of septic shock
137. Attenuation of tissue thrombosis and hemorrhage by ala-TFPI does not account for its protection against E. coli - A comparative study of treated and untreated non-surviving baboons challenged with LD100 E. coli
138. Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock
139. Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with Gram-negative peritonitis
140. Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock
141. Tissue factor pathway inhibitor dose-dependently inhibits coagulation activation without influencing the fibrinolytic and cytokine response during human endotoxemia
142. Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study
143. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection
144. Inhibition of Factor VIIa-tissue factor coagulation activity by a hybrid protein
145. Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins
146. The effect of two-domain tissue factor pathway inhibitor on endotoxin-induced disseminated intravascular coagulation in rabbits
147. Anticoagulant repertoire of the hookworm Ancylostoma caninum
148. Dose-response study of recombinant Factor VIIa/tissue factor inhibitor recombinant nematode anticoagulant protein c2 in prevention of postoperative venous thromboembolism in patients undergoing total knee replacement
149. Peptide exosite inhibitors of factor VIIa as anticoagulants
150. Selection and characterization of a new class of peptide exosite inhibitors of coagulation factor VIIa
151. Inhibitors of the tissue factor/factor VIIa-induced coagulation: Synthesis and in vitro evaluation of novel specific 2-aryl substituted 4H-3, 1-benzoxazin-4-ones
152. Effect of nafamostat mesilate, a synthetic protease inhibitor, on tissue factor-factor VIIa complex activity
153. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: A phase 2 dose-finding study
154. Dissociation of antithrombotic effect and bleeding time prolongation in rabbits by inhibiting tissue factor function